ArticleAnnals of Saudi medicine
Analysis of recurrence of risk factors after transcatheter bronchial artery embolization for hemoptysis.
Article in Annals of Saudi medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Predictors of Recurrence Following Bronchial Artery Embolisation (BAE) for Haemoptysis: A Systematic Review and Evidence Synthesis Analyses Using SWiM Guidelines.Cardiovascular and interventional radiology · 2026Pooled it
- Comment on: Risk factors of hemoptysis recurrence after BAE.Turk gogus kalp damar cerrahisi dergisi · 2026Article
- Risk Factors for the Recurrence of Massive Hemoptysis Treated With Bronchial Artery Embolization: A Retrospective Study.The clinical respiratory journal · 2026Article
- The Role of Preprocedural Computed Tomography Angiography in Enhancing Arterial Embolisation for Life-Threatening Haemoptysis: A Case Series.Advances in respiratory medicine · 2025Article
- The impact of pulmonary artery invasion on bronchial artery embolization in treating hemoptysis in lung cancer.European journal of radiology open · 2025Article
- Targeted bronchial artery embolization: a life-saving intervention for recurrent massive hemoptysis in bronchiectasis.Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery · 2025Article
- Bronchial Artery Embolisation in Haemoptysis Management: A Scoping Review with Emphasis on Embolic Materials and Indications.Advances in respiratory medicine · 2025Article
- Narrative review of the progress in the treatment of hemoptysis among patients with advanced lung cancer.Journal of thoracic disease · 2025Review
- Risk factors of hemoptysis recurrence after bronchial artery embolization and patient feedbacks.Turk gogus kalp damar cerrahisi dergisi · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs a proven and preferred technique for hemoptysis, bronchial artery embolization (BAE) cannot avoid the possibility of postoperative recurrence; however, few studies have examined the causes of hemoptysis recurrence after BAE.
objectivesIdentify the risk factors for hemoptysis recurrence after BAE treatment.
designRetrospective.
settingTertiary training and research hospital. PATIENTS AND
methodsA retrospective analysis was conducted on 406 patients with hemoptysis, 55 patients who developed with recurrent postembolization hemoptysis, covering the period from January 2011 to January 2021. Single factor analysis and multiple factor logistic regression were used to analyze high-risk factors for hemoptysis recurrence.
main outcome measuresThe incidence and risk factors for recurrence hemoptysis associated with transcatheter BAE. SAMPLE SIZE: 406 patients.
resultsMultivariate logistic regression analysis showed that preoperative computed tomography angiography (CTA) (odds ratio [OR]: 0.052, 95% CI: 0.012-0.225), tumor-related hemoptysis (OR: 20.753, 95% CI: 6.778-63.545), pleural thickening (OR: 3.168, 95% CI: 1.081-9.286), and bilateral lung lesions (OR: 8.442, 95% CI: 2.449-29.101) had a statistically significant impact on the recurrence of hemoptysis after BAE.
conclusionsPreoperative CTA serves as a protective factor against hemoptysis recurrence, whereas tumor-related hemoptysis, pleural thickening, and bilateral lung diseases are significant risk factors for hemoptysis recurrence following interventional therapy. LIMITATIONS: This was a retrospective analysis of a single center with a small sample, which may have a certain degree of recall bias when collecting data, thus, reducing the reliability of the results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.